Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The related topics section now omits Lung cancer and MedlinePlus Genetics, reducing navigational context but not changing the study’s core details; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-11T03:09:59.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Results data has been posted for the study (Results First Posted 2025-03-24). Enrollment and primary completion dates have been updated to reflect the latest status.
    Difference
    0.4%
    Check dated 2025-11-03T21:26:40.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    Lung cancer is added to related topics with a MedlinePlus Genetics link for educational resources.
    Difference
    0.2%
    Check dated 2025-10-27T20:46:22.000Z thumbnail image
  4. Check
    38 days ago
    Change Detected
    Summary
    Updated version to v3.2.0 and removed MedlinePlus Genetics topic: Lung cancer; added a government funding/operating status notice referencing NIH and OPM.
    Difference
    3%
    Check dated 2025-10-06T07:52:26.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    Core content updated with a new MedlinePlus Genetics topic on Lung cancer and a version upgrade to v3.1.0; older revision reference v3.0.2 was removed.
    Difference
    0.2%
    Check dated 2025-09-29T04:10:58.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    Removed a MedlinePlus Genetics topic entry for Lung cancer from the page, reducing coverage of that topic without adding new content.
    Difference
    0.2%
    Check dated 2025-09-22T00:38:34.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.